For the July 2026 period, on a consolidated basis, operating loss of \u25b31,998 million yen and net loss attributable to owners of the parent of \u25b31,851 million yen were recorded. Because the business model heavily depends on milestone revenue, earnings guidance for the 2027 period has not been disclosed. Development of regenerative medicine focused on redacetamid is continuing. Although cash and cash equivalents declined significantly versus the previous period, development funding through 2028 is secured. An earnings briefing material and an investor\/analyst briefing are planned.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4599","jir_company_name":"StemrIM Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4599-20260909-04.pdf","jir_short_summary":"For the July 2026 period, on a consolidated basis, operating loss of \u25b31,998 million yen and net loss attributable to owners of the parent of \u25b31,851 million yen were recorded. Because the business model heavily depends on milestone revenue, earnings guidance for the 2027 period has not been disclosed. Development of regenerative medicine focused on redacetamid is continuing. Although cash and cash equivalents declined significantly versus the previous period, development funding through 2028 is secured. An earnings briefing material and an investor\/analyst briefing are planned.","jir_summary":"### Overview of results\nThis period's consolidated results do not disclose net sales; ordinary loss was \u25b31,879 million yen and net loss attributable to owners of the parent was \u25b31,851 million yen. Given the business model's heavy reliance on milestone revenue, a rational earnings forecast for the July 2027 period is considered difficult to calculate and is not disclosed at this time. R&D expenses are increasing, with continued costs related to the development of redanosmitide. Cash and cash equivalents declined significantly, but development funds through 2028 are secured. An earnings briefing document and an IR\/analyst briefing are planned.\n\n### Outlook and capital position\nThe 2027 July period earnings forecast will not be disclosed; ongoing progress in the development of a leading regenerative medicine around redanosmitide and licensing negotiations are expected to continue. Although cash has declined significantly, assume R&D expenses of 1,300 million yen to 1,700 million yen and SG&A of 230 million yen to 310 million yen, and continue securing funding through 2038. Note that upfront payments from new alliances and the timing of milestone revenue are uncertain.","jir_financial_highlights":"Net loss for the period: \u25b31,851,498 thousand yen (Decrease from \u25b31,929,437 thousand yen in the previous period)\nSales: \uff0d (\uff0d)\nCash and cash equivalents: 2,177,035 thousand yen (YoY end\u25b34,817,556 thousand yen)\nTotal assets: 5,909,230 thousand yen (YoY end\u25b31,609,429 thousand yen)\nNet assets: 5,713,192 thousand yen (YoY end\u25b31,601,036 thousand yen)","jir_category":"","jir_hashtags":"#Stemrem, #Earnings, #RegenerativeMedicine, #Redacetamid","jir_key_figures":"Pre-tax loss for the period: \u25b31,849,546 thousand yen\nNet loss for the period (\u25b3): \u25b31,851,498 thousand yen\nEnding balance of cash and cash equivalents: 2,177,035 thousand yen","jir_meta_title":"\u3010Stemrem\u3011 FY2026 July Term Earnings Release | Key Losses and R&D Expenses","jir_meta_description":"Analysis of Stemrem's FY2026 July term financial results summary. Highlights include ordinary loss and net loss amounts, cash reduction, trends in R&D expenses, future outlook, and planned earnings briefing.","jir_og_title":"Stemrem FY2026 July Term Results \u2014 Losses and R&D Trends","jir_og_description":"Overview of Stemrem's FY2026 July term financial results summary. Concise summary of profit\/loss, cash balance, R&D expenses, and future outlook.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58113,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-111858","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n